PATENT CLAIM ANALYSIS

Application Number: 15903503
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-06
Patent Classification: ["514", "006400"]

Abstract:
What is described is a method for treating cancer in a patient in need of such treatment through the use of an antagonist to CXCR1 and/or CXCR2 receptors by administering a therapeutically effective amount of an antagonist of CXCR1 and/or CXCR2, or pharmaceutical compositions thereof, either alone as monotherapy, or in combination with at least one other anticancer therapy.

Claim (Index 17):
The method of  claim 2  wherein the cancer is selected from cancers of the prostate, colorectum, pancreas, cervix, stomach, endometrium, brain, liver, bladder, ovary, testis, head, neck, skin, mesothelial lining, blood, esophagus, breast, muscle, connective tissue, lung, adrenal gland, thyroid, kidney, lymphoid tissue, bone marrow or bone, glioblastoma, mesothelioma, renal cell carcinoma, gastric carcinoma, sarcoma, choriocarcinoma, cutaneous basocellular carcinoma, and testicular seminoma.

Metadata:
- Claim Count in Document: 49.0
- Percentile: 88.0
- Lexical Diversity: 1.34043
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15354936', '15627766', '13957665', '15279361', '14610960']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7855410920066307
- 35 USC 102 Novelty (BERT): 0.5925274683230659
- Combined Prediction Score: 0.7662397296382742
- Mean Citation Score: 342.598746
- Max Citation Score: 541.30383
- Similarity Product: 424.0728099915289

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test